Genmab A/S (GNMSF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
GNMSF Profit Margin, ROE & Profitability Analysis
GNMSF vs Healthcare Sector: How Genmab A/S Compares
How Genmab A/S compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Genmab A/S Stock Overvalued? GNMSF Valuation Analysis 2026
Based on fundamental analysis, Genmab A/S has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Genmab A/S Balance Sheet: GNMSF Debt, Cash & Liquidity
GNMSF Revenue Growth, EPS Growth & YoY Performance
GNMSF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Genmab A/S (CIK: 0001434265)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GNMSF
What is the AI rating for GNMSF?
Genmab A/S (GNMSF) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are GNMSF's key strengths?
Claude: Analysis in progress.
What are the risks of investing in GNMSF?
Claude: Analysis in progress.
What is GNMSF's revenue and growth?
Genmab A/S reported revenue of N/A.
Does GNMSF pay dividends?
Genmab A/S does not currently pay dividends.
Where can I find GNMSF SEC filings?
Official SEC filings for Genmab A/S (CIK: 0001434265) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GNMSF's EPS?
Genmab A/S has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is GNMSF's fundamental grade?
Based on our AI fundamental analysis in May 2026, Genmab A/S has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is GNMSF stock overvalued or undervalued?
Valuation metrics for GNMSF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is GNMSF's AI grade for 2026?
Our dual AI analysis gives Genmab A/S a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GNMSF's free cash flow?
Genmab A/S's operating cash flow is N/A, with capital expenditures of N/A.
How does GNMSF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).